BioSpace News Archive

New appointments include Ron Holder, COO, and Albert Hwang, CMO; both of whom bring proven records leading organizations with a focus on efficiency, innovation and growth

Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) for the use of the company’s elio™ tissue complete assay in a Merck trial of pembrolizumab-based combination therapy.

Biocon Biologics, a fully integrated ‘pure play’ global biosimilars organisation, is taking forward its mission of unlocking affordable access to quality insulins for people with diabetes across the world.

Noblegen’s protein-rich euglena flour will be available to the US market immediately.

Today announced updates regarding the continued progress of its Phase III AP-013 clinical trial and its manufacturing facility.

Kit Check, the leader in automated medication management solutions for hospitals, announced that Codonics, the leader in patient safety and image documentation solutions, will be part of the “Works With Kit Check” program, a medication intelligence platform enabling hospital technology to make use of pre-tagged drug information.

Results of Phase 1 and 2 studies in BCG Unresponsive Non-Muscle Invasive Bladder Cancer in High Risk Carcinoma in Situ Disease Earn FDA Breakthrough Status for ImmunityBio’s IL-15 Superagonist Complex

This is the first patent issued protecting the method of use for the dipeptidase-1 (DPEP-1) inhibitor, cilastatin, for ischemia reperfusion injury, where DPEP-1 mediated inflammation plays a major role.

Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, announced that a new study of the Prequel™ Prenatal Screen was published online in the journal Prenatal Diagnosis.

Cognizance Biomarkers, LLC, a wholly-owned subsidiary of Evogen, Inc., a leader in proteomic and genomic-based testing for improved diagnosis and treatment of neurological disorders, today announced initiation of a clinical trial with Mayo Clinic that aims to confirm its blood-based protein biomarker test and algorithm accurately distinguish epileptic seizures (ES) from psychogenic nonepileptic seizures (PNES)